Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR

Academic Article

Abstract

  • © 2017 European Cystic Fibrosis Society Background Cavosonstat (N91115), an orally bioavailable inhibitor of S-nitrosoglutathione reductase, promotes cystic fibrosis transmembrane conductance regulator (CFTR) maturation and plasma membrane stability, with a mechanism of action complementary to CFTR correctors and potentiators. Methods A Phase I program evaluated pharmacokinetics, drug–drug interactions and safety of cavosonstat in healthy and cystic fibrosis (CF) subjects homozygous for F508del-CFTR. Exploratory outcomes included changes in sweat chloride in CF subjects. Results Cavosonstat was rapidly absorbed and demonstrated linear and predictable pharmacokinetics. Exposure was unaffected by a high-fat meal or rifampin-mediated effects on drug metabolism and transport. Cavosonstat was well tolerated, with no dose-limiting toxicities or significant safety findings. At the highest dose, significant reductions from baseline in sweat chloride were observed (− 4.1 mmol/L; P = 0.032) at day 28. Conclusions The favorable safety and clinical profile warrant further study of cavosonstat in CF. ClinicalTrials.gov Numbers: NCT02275936, NCT02013388, NCT02500667
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Donaldson SH; Solomon GM; Zeitlin PL; Flume PA; Casey A; McCoy K; Zemanick ET; Mandagere A; Troha JM; Shoemaker SA
  • Start Page

  • 371
  • End Page

  • 379
  • Volume

  • 16
  • Issue

  • 3